retatrutide and type 1 diabetes More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, glucagon receptors In the Phase Seeking Differentiation Through a Triple

Are proton pump inhibitors a new antidiabetic drug

I wasnt constantly thinking about food or dragging through the day anymore

You look at the label and see there are 5 mg of lyophilized (freeze-dried) peptide in the vial

Other common side effects include: Dizziness and lightheadedness, particularly during the first few weeks Fatigue and low energy , often related to reduced caloric intake Headaches , which typically resolve within the first month Sulfur burps , a distinctive and common complaint Diarrhea , which usually resolves as the body adjusts Injection site reactions including redness and mild swelling Less common but important considerations Some patients experience hair loss on GLP-1 medications

That suggests the final number in longer trials could be even higher

It is not terrible